MarketPulse

MASH treatment

8 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva Bolsters Leadership Ranks Ahead of Pivotal Lanifibranor Phase 3 Data

Inventiva appoints three senior executives to strengthen leadership before Phase 3 lanifibranor data readout expected Q4 2026.
BNTXIVAbiopharmaceuticalPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva Bolsters Executive Team Ahead of Critical Lanifibranor Phase 3 Data

Inventiva appoints three new executives to strengthen leadership before anticipated Phase 3 lanifibranor trial results expected in Q4 2026.
IVAGeneral CounselPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva Files 2025 Earnings as Cash Position Supports MASH Drug Development

Inventiva filed 2025 regulatory documents with €99.3M cash on hand, advancing lanifibranor Phase 3 trial for metabolic liver disease treatment.
IVAPhase 3 clinical trialfinancial results
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva Files Annual Reports With €230.9M Cash Pile Amid MASH Drug Development

Inventiva filed 2025 regulatory documents showing €230.9M cash reserves and €4.5M revenues while advancing lanifibranor in Phase 3 MASH trials.
IVAPhase 3 clinical trialfinancial results
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Two Biotech Stocks Poised to Outpace Summit Therapeutics Amid FDA Uncertainty

Summit Therapeutics faces FDA decision on ivonescimab by November 2026 amid efficacy concerns, while Axsome and Madrigal positioned for outperformance.
AXSMMDGLSMMTregulatory riskFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva to Report 2025 Results as MASH Drug Candidate Advances

Inventiva will release 2025 financial results March 30, 2026, while advancing lanifibranor in Phase 3 MASH trials.
IVAPhase 3 clinical trialfinancial results
GlobeNewswire Inc.GlobeNewswire Inc.··Inventiva

Inventiva Reports €99.3M Cash Position Following $172.5M Capital Raise

Inventiva raises $172.5M, boosting cash position to €99.3M and extending runway through mid-2027 to fund MASH therapy development.
IVAcash positionfinancing
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva Strengthens Balance Sheet With $172.5M Offering; Eyes Mid-2027 Cash Runway

Inventiva raises $172.5M, strengthening balance sheet to €230.9M in liquidity. Clinical-stage biotech projects cash runway through mid-2027 to advance MASH treatment program.
IVApublic offeringclinical-stage biopharmaceutical